Clinical Trials
HaemaLogiX Doses First Patient with KMCAR T-Cell Therapy in Phase 1 Multiple Myeloma Trial
First patient safely dosed in Phase 1 KOALA trial evaluating KMCAR™ T-cell therapy in patients with relapsed/refractory kappa-restricted multiple m...
August 27, 2026 | News
WuXi XDC H1 2026 Revenue Jumps 37% to RMB 3.7 Bn on Strong Bioconjugate Demand
Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER[1] basis (41.5% growth on a CER[2]...
August 26, 2026 | Company results
Antengene’s ATG-201 Wins Australian Clearance for Phase I Autoimmune Disease Trial
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, develop...
August 26, 2026 | News
Pulnovo Medical Enrols First Patients in PULSE-LHD Trial for Pulmonary Hypertension
Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), announced the enrollment of the f...
August 24, 2026 | News
Akeso Secures China Clinical Trial Clearance for B7-H3 ADC AK157D1
Akeso, Inc. announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearanc...
August 24, 2026 | News
Leads Biolabs’ Opamtistomig NDA Accepted in China for Advanced EP-NEC
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation (CDE) of China'...
August 24, 2026 | News
CureGene Doses First Subject in Australia Phase I Trial of Oral Metabolic Drug CG-0416
CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist...
August 24, 2026 | News
Ingenia Therapeutics Debuts on KOSDAQ to Accelerate Next-Gen Vascular Antibody Pipeline
Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced that its shares have begun t...
August 21, 2026 | News
Harbour BioMed Secures China IND Approval for HBM7004 Bispecific Antibody in Advanced Solid Tumours
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...
August 20, 2026 | News
Singapore HSA Approves GSK’s Blenrep Combinations for Relapsed or Refractory Multiple Myeloma
Two head-to-head phase III trials demonstrated superior efficacy, including overall survival versus a daratumumab-based triplet in DREAMM-7 Blenrep, a f...
August 20, 2026 | News
OncoC4 Doses First Patient in Phase I Trial of neoCD24-Targeting T-Cell Engager ONC-783
— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous f...
August 19, 2026 | News
Connext Completes Phase 2 Enrollment of CNT201 for Dupuytren’s Contracture
All 56 planned participants enrolled approximately five months after first patient dosing - Topline Phase 2 data expected in late 2026 - Positive d...
August 19, 2026 | News
JW Pharmaceutical’s Epaminurad Shows Statistical Superiority in Phase III Gout Trial
-JW Pharmaceutical (KRX:001060) announced that the multinational Phase 3 clinical trial of its gout treatment candidate ‘Epaminurad (code name U...
August 18, 2026 | News
AbelZeta Secures US FDA IND Clearance for Bispecific CAR-T Therapy C-CAR039 in Large B-cell Lymphoma
AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovati...
August 18, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
